OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

ICPC Korea University Team Proteogenomically Characterizes Early-Onset Gastric Cancer

The incidence of early-onset gastric cancer (EOGC), a type of cancer that occurs in younger patients and found throughout the stomach, is markedly elevated in the Republic of Korea. As a country with the highest rates worldwide in both sexes, there is a need to identify molecular...


Proteogenomics Approach Identifies DPYSL3 Gene in Triple-Negative Breast Cancer

Claudin-Low (CLOW) tumors are classified as a subset of triple-negative breast cancers and account for a minority of breast cancer cases. But until now, there has been little study of their unique biological features. Understanding the biology of CLOW tumors is important for designing targeted...


Final Announcement: PrecisionFDA NCI-CPTAC Multi-omics Challenge Ends in Four Days

The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just four days left to submit your computational algorithms. Remember...


CPTAC Contributes to In-Depth Profiling of CAR T-Cell Signaling

CAR T-cells, which are immune cells reprogrammed to fight cancer, are promising novel cancer therapies to treat certain types of tumors. But, the underlying biological pathways that lead to remission or toxicity are not fully understood. In a study published in...


PrecisionFDA NCI-CPTAC Multi-Omics Challenge Deadline Approaching

The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just two weeks left to submit your compuational algorithms. Remember, if you did not participate in sub-challenge 1, you can still participate in sub-challenge 2.


PrecisionFDA NCI-CPTAC Multi-Omics Challenge Launches Sub-Challenge 2

The second data release for the NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge has launched!  If you did not participate in sub-challenge 1 (submission 1), you can still participate in sub-challenge 2 (submission 2).


CPTAC Contributes to the Identification of a Novel Pharmacodynamic Biomarker for Clinical Trial Use

Several ongoing Phase I clinical trials are assessing the safety and tolerability of ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-Related) inhibitors when administered alone or in combination with existing therapies. ATM and ATR are attractive therapeutic targets...


PrecisionFDA NCI-CPTAC Multi-Omics Challenge Updates

The security of precisionFDA users’ personal information and data is of critical importance. To strengthen the safeguards already in place, precisionFDA will be introducing several changes to achieve compliance with the FedRAMP and FISMA Moderate security standards. These changes will take...


CPTAC Releases UCEC, ccRCC Discovery Data and Other Study Datasets

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is releasing the latest proteomic discovery datasets for Uterine Corpus Endometrial Carcinoma (UCEC) and Clear Cell Renal Cell Carcinoma (ccRCC). CPTAC has previously demonstrated how proteogenomics reveals new insights into cancer biology...


CPTAC Develops Fit-for-Purpose Immuno-MRM Assay for FANCD2 Protein Modification Involved in DNA Damage

Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure and an increased risk of developing certain types of cancer. The FA pathway consists of a network of 21...


Pages